Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$1.53 +12.5%	$1.34	$0.86 ▼ $3.36	$82.38M	0.14	232,796 shs	919,417 shs
BCAB BioAtla	$0.36 -0.4%	$0.38	$0.24 ▼ $2.53	$21M	0.9	530,581 shs	504,140 shs
EXOZ eXoZymes	$9.31	$10.07	$8.50 ▼ $23.99	$78.08M	N/A	1,803 shs	794 shs
SRZN Surrozen	$11.22 -1.1%	$9.46	$5.90 ▼ $18.17	$97.18M	0.6	14,779 shs	7,857 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	-3.55%	-2.86%	-18.56%	+33.33%	-52.28%
BCAB BioAtla	-4.72%	-1.79%	+4.78%	-8.31%	-81.08%
EXOZ eXoZymes	-4.81%	-6.81%	+1.31%	-37.52%	+930,999,900.00%
SRZN Surrozen	-1.30%	+4.61%	+31.21%	+42.59%	+54.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABOS Acumen Pharmaceuticals	3.0984 of 5 stars	3.5	5.0	0.0	0.0	1.4	1.7	0.6
BCAB BioAtla	2.3345 of 5 stars	3.0	3.0	0.0	0.0	1.4	2.5	0.6
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	2.7942 of 5 stars	3.5	2.0	0.0	0.0	2.9	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	3.00	Buy	$6.33	313.94% Upside
BCAB BioAtla	2.00	Hold	$5.00	1,303.71% Upside
EXOZ eXoZymes	0.00	N/A	N/A	N/A
SRZN Surrozen	3.00	Buy	$38.50	243.14% Upside

Current Analyst Ratings Breakdown

Latest BCAB, ABOS, EXOZ, and SRZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	BCAB BioAtla	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
8/13/2025	BCAB BioAtla	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
6/17/2025	ABOS Acumen Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$1.93 per share	N/A
BCAB BioAtla	$11M	1.90	N/A	N/A	($0.29) per share	-1.23
EXOZ eXoZymes	$70K	1,115.87	N/A	N/A	$0.86 per share	10.83
SRZN Surrozen	$10.65M	9.02	N/A	N/A	$5.50 per share	2.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$102.33M	-$2.28	N/A	N/A	N/A	N/A	-81.39%	-61.96%	N/A
BCAB BioAtla	-$69.78M	-$1.10	N/A	N/A	N/A	N/A	-1,177.18%	-137.51%	11/6/2025 (Estimated)
EXOZ eXoZymes	-$5.86M	N/A	0.00	∞	N/A	N/A	-134.50%	-81.63%	N/A
SRZN Surrozen	-$63.56M	-$14.42	N/A	N/A	N/A	-274.42%	-545.43%	-64.40%	11/5/2025 (Estimated)

Latest BCAB, ABOS, EXOZ, and SRZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ABOS Acumen Pharmaceuticals	-$0.54	-$0.68	-$0.14	-$0.68	N/A	N/A
8/12/2025	Q2 2025	EXOZ eXoZymes	N/A	-$0.28	N/A	-$0.28	N/A	N/A
8/8/2025	Q2 2025	SRZN Surrozen	-$1.23	-$1.14	+$0.09	$2.55	N/A	$0.98 million
8/7/2025	Q2 2025	BCAB BioAtla	-$0.29	-$0.31	-$0.02	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BCAB BioAtla	N/A	N/A	N/A	N/A	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.26	5.97	5.97
BCAB BioAtla	N/A	1.24	1.24
EXOZ eXoZymes	0.01	6.19	6.19
SRZN Surrozen	N/A	16.41	16.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
BCAB BioAtla	77.23%
EXOZ eXoZymes	N/A
SRZN Surrozen	66.57%

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	9.30%
BCAB BioAtla	11.22%
EXOZ eXoZymes	72.41%
SRZN Surrozen	45.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	20	60.57 million	54.94 million	Optionable
BCAB BioAtla	60	58.72 million	52.13 million	Optionable
EXOZ eXoZymes	29	8.39 million	2.31 million	N/A
SRZN Surrozen	80	8.56 million	4.69 million	Not Optionable

BCAB, ABOS, EXOZ, and SRZN Headlines

Recent News About These Companies

HC Wainwright Issues Positive Forecast for Surrozen Earnings

August 16, 2025 | marketbeat.com

HC Wainwright Issues Positive Estimate for Surrozen Earnings

August 16, 2025 | americanbankingnews.com

Surrozen (NASDAQ:SRZN) Issues Earnings Results

August 11, 2025 | marketbeat.com

Vivo Capital LLC Takes Position in Surrozen, Inc. (NASDAQ:SRZN)

August 9, 2025 | marketbeat.com

Surrozen (NASDAQ:SRZN) Stock Price Down 12.8% - Should You Sell?

August 9, 2025 | marketbeat.com

Surrozen’s Q2 2025: Progress in Eye Disease Therapies

August 8, 2025 | tipranks.com

Surrozen Reports Q2 Profit on Gains

August 8, 2025 | fool.com

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

August 8, 2025 | globenewswire.com

Surrozen to Present at Upcoming Healthcare Investor Conference

August 6, 2025 | globenewswire.com

Surrozen (SRZN) Projected to Post Earnings on Monday

August 5, 2025 | marketbeat.com

We Think Surrozen (NASDAQ:SRZN) Can Afford To Drive Business Growth

July 1, 2025 | finance.yahoo.com

Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround

May 16, 2025 | zacks.com

Surrozen secures patent for tissue repair technology

May 15, 2025 | investing.com

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

May 14, 2025 | globenewswire.com

Surrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 10, 2025 | finanznachrichten.de

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025 | globenewswire.com

Surrozen files to sell 5.21M shares of common stock for holders

April 25, 2025 | markets.businessinsider.com

Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year

April 2, 2025 | markets.businessinsider.com

Insiders Are Loving These 5 Tech and Biotech Stocks

April 2, 2025 | 247wallst.com

Surrozen Focuses on Ophthalmology Amid Financial Challenges

April 1, 2025 | tipranks.com

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

March 31, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB, ABOS, EXOZ, and SRZN Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$1.53 +0.17 (+12.50%)

Closing price 04:00 PM Eastern

Extended Trading

$1.52 -0.01 (-0.33%)

As of 07:55 PM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

BioAtla NASDAQ:BCAB

$0.36 0.00 (-0.39%)

Closing price 04:00 PM Eastern

Extended Trading

$0.37 +0.01 (+3.03%)

As of 07:28 PM Eastern

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

eXoZymes NASDAQ:EXOZ

$9.31 0.00 (0.00%)

As of 03:53 PM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

Surrozen NASDAQ:SRZN

$11.22 -0.13 (-1.15%)

As of 04:00 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time